Home | Welcome to Contract Pharma   
Last Updated Saturday, December 20 2014

Print RSS Feed

Ligand Earns Milestone for NOXAFIL Approval



By Kristin Brooks



Published March 17, 2014
Related Searches: formulation
Ligand Pharmaceuticals Inc.has earned a $1 million milestone payment from Merck following the FDA approval of NOXAFIL (posaconazole) injection (18 mg/mL), a new Captisol-enabled formulation for intravenous use. Under a commercial supply agreement, Ligand will sell Captisol to Merck for this product.
 
“We congratulate the project team at Merck on this important advancement in the treatment of invasive fungal infections,” said John Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Ligand's business is thriving with the continued success of our partners with late-stage clinical and regulatory events. This is the second new product expected to be made available in 2014 following the launch of Duavee last month by Pfizer and three additional Ligand-partnered programs are pending approvals in 2014. Captisol is a proven formulation that is garnering more interest by prospective customers and partners given the technology’s elevated profile.”
 
NOXAFIL injection for intravenous use is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who severely immunocompromised.


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On